Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk ...

Eikonizo Therapeutics, a biopharmaceutical company dedicated to developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases announced ...

Co. Ltd. has divulged compounds acting as histone deacetylase 1 (HDAC1) and/or 2 (HDAC2) inhibitors reported to be useful for the treatment of cancer.

Greeny, A, Nair, A, Sadanandan, P, Satarker, S, Famurewa, AC and Nampoothiri, M (2024) Epigenetic Alterations in Alzheimer's ...

Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse ...

As with other disease states, biomarkers that can provide value across diagnosis, prognosis, and treatment response, have ...

According to the experimental group, the hippocampus samples were gently added into the gel plate sample hole made of 10% separation glue solution and 5% concentrated glue ... Studies have found that ...

The researchers found partial responses in three patients (objective response rate, 11 percent), with a median response ...

Most mutants died at approximately 10 weeks without obvious correlation between physical deterioration and time of death. Heterozygous mutant females seemed normal for the first four months ...

This is the first comprehensive immunohistochemical analysis of the expression of several class I HDAC proteins (1, 2 and 3) in urothelial carcinoma. In our study, we found all three isoforms in a ...

Body Dimensions 163.4 x 76.1 x 8.9 mm (6.43 x 3.00 x 0.35 in) ...